Discovery of a New Compound, Erinacerin W, from the Mycelia of Hericium erinaceus, with Immunomodulatory and Neuroprotective Effects

• Published in: Molecules (Basel, Switzerland) Vol. 29; no. 4; p. 812
• Main Authors: Lin, Jing-Yi, Chen, Yen-Po, Lin, Ting-Wei, Li, Tsung-Ju, Chen, Yu-Wen, Li, I-Chen, Chen, Chin-Chu
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 09.02.2024; MDPI
• Subjects: Carbon; Communication; Drug dosages; erinacerin W; Hericium; Hericium erinaceus mycelia; Humans; Immunomodulators; immunomodulatory; Lipopolysaccharides - pharmacology; Natural products; Neuroblastoma; neuroprotection; Neuroprotective Agents - pharmacology; NMR; novel compound; Traditional Chinese medicine; NMR; erinacerin W; neuroprotection; novel compound; Hericium erinaceus mycelia; immunomodulatory
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules29040812

One new compound with an isoindolinone skeleton, along with erinacines A, C, and S, was isolated from the mycelia of Hericium erinaceus, an edible fungus with a long history of use in traditional Chinese medicine. Based on analysis of MS and NMR spectral data, the structure of the compound was identified as (2E,6E)-8-(2-(1-carboxy-3-methylbutyl)-4,6-dihydroxy-1-oxoisoindolin-5-yl)-2,6-dimethylocta-2,6-dienoic acid. In light of this discovery, we have given this compound the name erinacerin W. Using a co-culture in vitro LPS-activated BV2 microglia-induced SH-SY5Y neuroinflammation model, the results showed that erinacerin W demonstrated protection against the LPS-activated BV-2 cell-induced overexpression of IL-6, IL-1β, and TNF-α on SH-SY5Y cells. This finding may provide potential therapeutic approaches for central nervous disorders.